Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Psyence Group Inc
(OP:
PSYGF
)
0.0280
UNCHANGED
Last Price
Updated: 11:24 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Psyence Group Inc
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Via
Benzinga
How To Finance A Psychedelics Business? Learn From These Four Companies
April 04, 2023
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering
Via
Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
March 27, 2023
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses
Via
Benzinga
Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
March 21, 2023
Psyence Partners with iNGENū for Palliative Care Clinical Trial
Via
Benzinga
Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce
January 24, 2023
Health Canada Oks Clinical-Grade MDMA Export To UK Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its manufacturing partners received a Health Canada export permit for no less...
Via
Benzinga
Psychedelics Travel: Clinical-Grade Magic Mushrooms Extract Exported From Southern Africa To UK
January 20, 2023
Lifesciences psychedelics biotech Psyence Group Inc. (OTCQB: PSYGF) recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in...
Via
Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
January 10, 2023
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space.
Via
Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
December 16, 2022
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).
Via
Benzinga
Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
December 15, 2022
Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal.
Via
Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
October 11, 2022
UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used...
Via
Benzinga
International Magic Mushrooms: Where Are They Produced And Where Are They Headed?
September 29, 2022
Psyence Group Inc.
Via
Benzinga
Psyched: Magic Mushrooms Vs. Psychotherapy, Psilocybin For Frontline Health Workers & Protecting Peyote
September 26, 2022
As a wave of news about psychedelics research and successful applications sweeps across the country and abroad, Psyched is back to wrap up the exciting movement of this rapidly evolving sector.
Via
Benzinga
Magic Mushrooms Vs. Psychotherapy For Incurable Cancer Diagnosis Moves Forward In UK Clinical Trials
September 19, 2022
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc.
Via
Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
April 25, 2022
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami...
Via
Benzinga
Psyence, Filament Strike Magic Mushroom Product Licensing Agreement: What You Need To Know
April 19, 2022
Psyence Group (OTCQB: PSYGF) and Filament Health Corp. (OTCQB: FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.